Video
Dr. Kishan calls for more prospective studies on the predictive nature of germline variants
Author(s):
“What really needs to be done to show that this works is to look prospectively,” says Amar U. Kishan, MD.
Video Player is loading.
In this video, Amar U. Kishan, MD, discusses the takeaways of the study, “Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.” Kishan is an associate professor in the department of radiation oncology, chief of genitourinary oncology service, and vice chair of clinical and translational research at the University of California, Los Angeles.
Related Videos
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Investigators evaluate tamsulosin use in pediatric patients
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Related Content
